ArticleJournal of fluorescence2025
Highly Fluorescent π-Conjugated Azomethines and Divalent Metal Complexes as Antibacterial and Antibiofilm Nominees.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fluorescent Chalcone-Based Macrocyclic Crown Ether as a Multifunctional Platform for Dye Removal and Antibacterial Activity: Synthesis, Characterization, and Docking Insights.Journal of fluorescence · 2026Article
- Biofilm-associated antibiotic tolerance in the era of multidrug resistance: quorum-sensing mechanisms and emerging therapeutic strategies.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
π-Conjugated azomethine ligands differing in the naphthalene or phenylmethane-centered core structure and their divalent cobalt, nickel, copper, and zinc metal complexes were prepared and well-characterized by spectral analyses in solid state. Magnetic natures of the complexes were determined by magnetic susceptibility measurements in solid-state. Their remarkable photophysical characteristics were recorded by Uv-vis and Fluorescence spectroscopic techniques. At their excitation wavelenght of 265 nm, all molecules exhibited triple fluorescence emission bands with promising intensities above 673 nm in near infra-red region. Antibacterial and antibiofilm activities of the π-conjugated azomethines are promising for potential applications in medical and healthcare settings. Hence, the antibacterial/antibiofilm activity of the π-conjugated azomethine ligands and their metal complexes against some clinically important bacteria namely Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa and Proteus mirabilis was investigated, and the obtained results have shown that the ligands and complexes had a remarkable antibacterial effect, especially on Proteus mirabilis. Metal complexes have been found to have a significant inhibitory effect on biofilm formation by MRSA, MSSA, and P. mirabilis compared to ligands. The copper (II) complex of ligand-2 showed the highest inhibition percentage, significantly reducing biofilm formation for MRSA and MSSA. Furthermore, cobalt (II) complexes of the ligands selectively inhibited the growth of the opportunistic pathogen P. mirabilis biofilms, indicating that metal complexes might be a good choice for future antibiofilm studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.